Opendata, web and dolomites

AutArt

Clinical validation of the AutArt rheumatoid arthritis diagnostic device

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AutArt project word cloud

Explore the words cloud of the AutArt project. It provides you a very rough idea of what is the project "AutArt" about.

treatments    moment    modifying    became    sharp    millions    lining    permanently    regular    dynamically    monitoring    decreased    establishment    patients    selling    causing    precise    scheduled    evaluation    market    contributes    causes    25    eur    282    2020    diagnoses    sale    drugs    mds    der    diagnostic    van    social    share    sas    people    joints    clinical    ray    2014    autoimmune    first    toolkit    sold    action    provides    group    rising    comparability    bone    medical    device    detection    scoring    destroy    estimate    image    precision    billion    rheumatoid    50    union    regulation    health    diagnosis    validation    economic    agents    inflammation    automatically    consists    disease    disabled    million    companies    objectivity    30    sustainability    cartilage    intensive    healthcare    biologic    considerably    chronic    treatment    feasibility    15    time    line    successful    software    follow    heijde    points    progression    serious    pharmaceutical    deformity    service    autart    ra    ten    arthritis    act    competitors    ineffective    2009   

Project "AutArt" data sheet

The following table provides information about the project.

Coordinator
BIFARMA SZOFTVERFEJLESZTO ES TANACSADO KORLATOLT FELELOSSEGU TARSASAG 

Organization address
address: SZABOLCSKA MIHALY UTCA 1 FSZT 3
city: BUDAPEST
postcode: 1114
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Hungary [HU]
 Project website http://www.bifarma.hu
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIFARMA SZOFTVERFEJLESZTO ES TANACSADO KORLATOLT FELELOSSEGU TARSASAG HU (BUDAPEST) coordinator 50˙000.00

Map

 Project objective

The AutArt diagnostic toolkit is a medical device that automatically diagnoses the progression of Rheumatoid Arthritis (RA) on an X-Ray image by using the Sharp/van der Heijde scoring system. This Phase 1 feasibility study will support the clinical validation of the device in Phase 2 that we estimate will cost between 1.5-2 million EUR; with the first market sale scheduled within 2 years, sold SAS (Software as a Service). RA is a chronic autoimmune disease that causes inflammation of the lining of the joints, which can destroy cartilage and bone, causing deformity of the joints. RA is a serious economic and social problem, 20-30% of early RA patients become permanently work disabled during the first 2-3 years of the disease and more than 50% of patients with RA became work disabled during the first ten years of the disease. Classical disease-modifying drugs are ineffective in about 10-15% of the cases, furthermore, biologic agents may also be ineffective. Early detection, regular clinical monitoring and comparable, objective evaluation is essential for successful treatment. The AutArt medical device is the result of 2 years of intensive R&D and at the moment there are no serious competitors in the market, so this is the time to act for a dynamically rising market share in the RA diagnostic market. The target group consists of MDs, medical institutions and pharmaceutical companies. The unique selling points of the product are objectivity, comparability and precision. In the EU, RA treatments cost 25.1 billion EUR in 2009. With more precise diagnosis and objective follow-up this can be decreased considerably with the AutArt medical device. This project is in line with the 282/2014/EU regulation on the establishment of a third Programme for the Union’s action in the field of health (2014-2020) because it contributes to the sustainability of the healthcare system and provides millions of people with better treatment through more precise diagnosis.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AUTART" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AUTART" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More